Methotrexate and emerging therapies

Rheumatic Disease Clinics of North America

Volumn 24, Issue 3, 1998, Pages 651-658

  Kremer, J M ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SALAZOSULFAPYRIDINE;

CANCER; DRUG COST; DRUG MONITORING; DRUG TOXICITY; HUMAN; LIVER TOXICITY; LUNG TOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031669803     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70032-6     Document Type: Article

References (23)

1. G.S. Alarcón J.M. Kremer M. Macaluso Risk factors associated with lung injury in methotrexate-treated rheumatoid arthritis patients: A multicenter, case-control study Ann Intern Med 127 1997 356 364
2. B.N. Cronstein Molecular therapeutics. Methotrexate and its mechanism of action Arthritis Rheum 39 1996 1951 1960
3. D.E. Furst N. Erikson L. Clute Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis J Rheumatol 17 1990 1628 1635
4. L. Georgescu G.C. Quinn S. Schwartzman Lymphoma in patients with rheumatoid arthritis: Association with the disease state or methotrexate treatment Sem Arthritis Rheum 26 1997 794
5. G. Gridley J.K. McLaughlin A. Ekbom Incidence of cancer among patients with rheumatoid arthritis J Natl Cancer Inst 85 1993 307 311
6. J.M. Kremer Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis Br J Rheumatol 34 Suppl z 1995 26 29
7. J.M. Kremer Safety, efficacy and mortality in a long-term cohort of patients with RA on methotrexate: Follow-up after a mean of 13.3 years Arthritis Rheum 40 1997 984 985
8. J.M. Kremer G.S. Alarcón R.W. Lightfoot Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity Arthritis Rheum 37 1994 316 328
9. J.M. Kremer G.S. Alarcón M.E. Weinblatt Clinical, laboratory, radiographic and histopathologic features of methotrexate lung injury in patients with rheumatoid arthritis: A multi-center study with literature review Arthritis Rheum 40 1997 1829 1837
10. J.M. Kremer D. Furst M.E. Weinblatt Significant changes in serum AST across hepatic histological biopsy grades: An analysis of 3 prospective cohorts on methotrexate therapy for rheumatoid arthritis J Rheumatol 23 1996 459 461
11. J.M. Kremer J.K. Lee The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis Arthritis Rheum 29 1986 822 831
12. J.M. Kremer J.K. Lee A long-term prospective study of the use of methotrexate in rheumatoid arthritis: Update after a mean of 53 months Arthritis Rheum 31 1988 577 584
13. J.M. Kremer C.T. Phelps Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: Update after a mean of 90 months Arthritis Rheum 35 1992 138 145
14. P. Miossec W. VandenBerg Review: TH1/TH2 cytokine balance in arthritis Arthritis Rheum 12 1997 2105 2115
15. J.R. O'Dell C.E. Haire N. Erickson Treatment of rheumatoid arthritis with methotrexate, sulfasalazine and hydrochloroquine, or a combination of these medications N Engl J Med 334 1996 1287 1291
16. P. Tugwell T. Pincus D. Yocum Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis N Engl J Med 333 1995 137 141
17. M.E. Weinblatt J.S. Coblyn D.A. Fox Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 312 1985 818 822
18. M.E. Weinblatt H. Kaplan B.F. Germain Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: A thirty-six-week, double-blind trial Arthritis Rheum 33 1990 330 338
19. M.E. Weinblatt D.E. Trentham P.A. Fraser Long-term prospective trial of low dose methotrexate in rheumatoid arthritis Arthritis Rheum 31 1988 167 175
20. M.E. Weinblatt B.N. Weissman D.E. Holdsworth Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84 month update Arthritis Rheum 35 1992 129 137
21. H.J. Williams J.R. Ward J.C. Reading Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial Arthritis Rheum 35 1992 259 269
22. H.J. Williams R.F. Wilkens Samuelson C.O. Jr Comparison of low-dose pulse methotrexate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial Arthritis Rheum 28 1985 822 831
23. F. Wolfe D.J. Hawley M.A. Cathey Termination of slow-acting antirheumatic therapy in rheumatoid arthritis: A 14 year prospective evaluation of 1017 consecutive starts J Rheumatol 17 1990 994 1002